Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cocrystal Pharma Inc. COCP

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).


Recent & Breaking News (NDAQ:COCP)

Cocrystal Pharma Announces Participation in Virtual Investor Events

GlobeNewswire 5 days ago

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Newsfile 8 days ago

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

GlobeNewswire December 19, 2022

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

GlobeNewswire December 1, 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

GlobeNewswire November 17, 2022

Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

GlobeNewswire November 14, 2022

Cocrystal Pharma to Participate in Two Investor Conferences in November

GlobeNewswire November 2, 2022

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

GlobeNewswire November 1, 2022

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344

GlobeNewswire October 26, 2022

Cocrystal Pharma to Present at the LD Micro Main Event XV

GlobeNewswire October 19, 2022

Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022

GlobeNewswire October 13, 2022

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19

GlobeNewswire October 11, 2022

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

GlobeNewswire October 5, 2022

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

GlobeNewswire October 3, 2022

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire September 6, 2022

Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

GlobeNewswire August 15, 2022

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

GlobeNewswire August 8, 2022

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Newsfile August 3, 2022

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

GlobeNewswire July 14, 2022

Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

GlobeNewswire June 1, 2022